Umbilical cord blood as a promising source of NK cells for immunotherapy

Currently, a large number of studies on genetic modification cord blood NK cells (UCB-NK) are carried out at both clinical and preclinical levels. Immunotherapy based UCB-NK has great potential for antitumor therapy. However, despite having known several advantages over peripheral (PB- NK), including high concentration in low virulence rate, predominantly characterized the scientific literature as immature low-functioning cells. In this work, we studied phenotypic characteristics possibility stimulatory compensation decreased functional activity Our revealed can be poorly differentiated weakly activated with level inhibitory receptor NKG2A activating NKG2C HLA-DR, accordingly data. Two types stimuli were chosen to stimulate freshly isolated cells: 1) 100 units IL-2; 2) combinations IL-2 K-562 feeder expressing membrane-bound IL-21 (K562-mbIL21). It was shown degranulation (LAMP-1) proliferative higher than parallel cultured ex vivo PB-NK under same conditions stimulated 7 days + K562-mbIL21. Moreover, stimulation way K562-mbIL21 seemed more perspective obtain proliferatively active compared only. Since is promising improve properties cells, retroviral transduction procedure performed study transduced day 8 cultivation. study, used targeted overexpression adaptor molecule DAP12, which involved signaling cell receptors. equal experimental volume viral particles. As result, efficiency found 4-fold Thus, appear tool further research cancer immunotherapy.